General Announcement::Glenmark and Bausch Health join together to commercialize RYALTRIS nasal spray in Canada

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
22-Mar-2021 13:28:56
Status
New
Announcement Sub Title
Glenmark and Bausch Health join together to commercialize RYALTRIS nasal spray in Canada
Announcement Reference
SG210322OTHR84Q8
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
22/03/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark and Bausch Health join together to commercialize RYALTRIS nasal spray in Canada

Attachments

SGX_PR_22032021.pdf
Total size =342K